Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RNA NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRNAAvidity Biosciences$46.35+3.8%$35.63$21.51▼$56.00$5.75B0.953.90 million shs1.89 million shsSRPTSarepta Therapeutics$20.22+0.8%$17.99$10.41▼$143.49$1.96B0.4616.05 million shs9.52 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRNAAvidity Biosciences+0.72%-3.06%+33.19%+46.04%-0.80%SRPTSarepta Therapeutics-2.53%-1.18%+47.39%-47.07%-86.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRNAAvidity Biosciences3.2033 of 5 stars4.52.00.00.03.90.80.0SRPTSarepta Therapeutics4.6445 of 5 stars4.02.00.04.22.41.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRNAAvidity Biosciences 3.06Buy$67.0044.55% UpsideSRPTSarepta Therapeutics 2.07Hold$43.50115.13% UpsideCurrent Analyst Ratings BreakdownLatest RNA and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$17.008/15/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSell ➝ Sell$12.008/8/2025RNAAvidity BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $75.008/8/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$59.00 ➝ $62.008/8/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.008/7/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.008/7/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$48.00 ➝ $50.007/29/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$22.007/29/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform7/29/2025SRPTSarepta TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Perform ➝ Market Perform$25.00 ➝ $50.007/29/2025SRPTSarepta TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $20.00(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRNAAvidity Biosciences$10.90M547.06N/AN/A$9.27 per share5.00SRPTSarepta Therapeutics$1.90B1.04$2.46 per share8.23$13.89 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A1.85N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest RNA and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRNAAvidity BiosciencesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRNAAvidity BiosciencesN/A9.269.26SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRNAAvidity BiosciencesN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipRNAAvidity Biosciences3.83%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRNAAvidity Biosciences190128.65 million123.73 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableRNA and SRPT HeadlinesRecent News About These CompaniesLevi & Korsinsky Reminds Sarepta Therapeutics, Inc. Investors of the Pending Class Action ...4 hours ago | reflector.comRLevi & Korsinsky Reminds Sarepta Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – SRPTAugust 22 at 4:30 PM | globenewswire.comSRPT Deadline: SRPT Investors with Losses in Excess of $100K Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud LawsuitAugust 22 at 2:49 PM | prnewswire.comINVESTOR DEADLINE MONDAY: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPTAugust 22 at 2:00 PM | prnewswire.comSarepta Therapeutics: A Strong Opportunity Amidst The PanicAugust 22 at 12:50 PM | seekingalpha.comSRPT 3-DAY DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 DeadlineAugust 22 at 11:46 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPTAugust 22 at 10:00 AM | prnewswire.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Bank of America Analyst SaysAugust 22 at 9:07 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Short Interest UpdateAugust 22 at 6:40 AM | marketbeat.comBank of America Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $17.00August 22 at 2:40 AM | americanbankingnews.comSRPT FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action – SRPTAugust 21 at 9:19 PM | globenewswire.comINVESTOR DEADLINE AUGUST 25: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPTAugust 21 at 4:30 PM | prnewswire.comSarepta: A Dizzying Pivot From Gene Therapy Peril To An RNA Future (Rating Downgrade)August 21 at 4:26 PM | seekingalpha.comSAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th DeadlineAugust 21 at 4:04 PM | globenewswire.comSarepta Therapeutics (SRPT): B of A Securities Lowers Price Target | SRPT Stock NewsAugust 21 at 3:31 PM | gurufocus.comSarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SRPTAugust 21 at 3:07 PM | globenewswire.comSarepta Therapeutics stock falls after refinancing convertible notesAugust 21 at 12:44 PM | za.investing.comSarepta Therapeutics shares dip after convertible note refinancingAugust 21 at 12:44 PM | msn.comSarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027August 21 at 12:44 PM | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPTAugust 21 at 10:32 AM | globenewswire.comClass Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact The Gross Law FirmAugust 21 at 8:45 AM | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025Brutal 2025 for Sarepta—Analysts Still Call for 179% UpsideBy Leo Miller | August 12, 2025RNA and SRPT Company DescriptionsAvidity Biosciences NASDAQ:RNA$46.35 +1.69 (+3.78%) Closing price 04:00 PM EasternExtended Trading$46.45 +0.10 (+0.22%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Sarepta Therapeutics NASDAQ:SRPT$20.22 +0.16 (+0.80%) Closing price 04:00 PM EasternExtended Trading$20.18 -0.04 (-0.22%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access